|
|
Article: Anadys Pharmaceuticals and LG Life Sciences Announce Phase II Clinical Trial of ANA380 (LB80380) in Patients with Drug-Resistant Hepatitis B Virus Infection.
- Article from:
- PR Newswire
- Article date:
- September 14, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
More Than Two-Thirds of Patients Develop Resistance to Common Hepatitis B Drug Lamivudine After Four Years of Treatment
Anadys Pharmaceuticals, Inc. and LG Life Sciences, Ltd. (KOSPI: 68870) today announced that the first two cohorts have completed enrollment in a Phase II clinical trial of ANA380 (LB80380) in patients with lamivudine- resistant hepatitis B virus (HBV) infection. ANA380 is an antiviral compound that has exhibited potent activity against HBV, including in vitro activity against HBV strains resistant to lamivudine, the current standard of treatment for patients infected with HBV. Previously reported results from a completed Phase I/IIa clinical ...